Inside the research

LeMaitre Vascular, Inc.

LMAT Research profile · latest available data

Price overview

$81.52

▲ +0.70 (+0.9%)

52w hi$116.75
52w lo$78.76
Vol230.30K
As of25 Sep 2026

The Verdict

Hold

Our score -0.35

Short-0.63
Medium-0.27
Long+0.06

computed 2026-09-27

Key fundamentals

LeMaitre Vascular, Inc.

Healthcare · Medical Instruments & Supplies

Market cap$1.86B
Enterprise value$1.68B
Trailing P/E28.50x
Forward P/E25.65x
EV / EBITDA20.22x
P / S (ttm)7.10x
Profit margin25.0%
Return on equity16.8%
Revenue growth+9.6%
Earnings growth+22.6%
Debt / equity45.26

Layer Breakdown

LayerRawContribution
Fundamental+0.23
Sector+0.08
Technical-0.44
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

United States · www.lemaitre.com

Risk Metrics

Beta vs SPX0.65
Corr SPX0.26
Annual vol40.1%
Annual ret+3.3%
Sharpe0.08
Max DD-32.9%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-08-04Earnings Release, Exhibitsread
2026-06-05Shareholder Voteread
2026-05-05Earnings Release, Exhibitsread
2026-04-14Officer / Director Change, Other Material Eventread
2026-02-25Earnings Release, Exhibitsread
2025-11-06Earnings Release, Exhibitsread
2025-08-05Earnings Release, Exhibitsread
2025-06-03Shareholder Voteread
2025-05-01Earnings Release, Exhibitsread
2025-02-27Earnings Release, Exhibitsread
2025-02-13Officer / Director Change, Exhibitsread
2024-12-19Material Agreement, Material Obligation…read

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders8
Top-5 share98.9%
HHI4,010 (concentrated)

Top Holders

HolderValueShares
State Street Corp$86.50M901.42K
Capital Research / Capital World$23.78M247.80K
Renaissance Technologies$16.27M169.50K
Citadel Advisors$16.19M15.25M
AQR Capital Management$1.98M20.62K
Millennium Management$863.06K8.99K
Fidelity / FMR LLC$618.36K6.44K
T. Rowe Price Group$72.47K755.14K

As of 2026-06-30

SEC Filings

DateFormDoc
2026-08-0510-Qview
2026-08-048-Kview
2026-06-054view
2026-06-054view
2026-06-054view
2026-06-054view
2026-06-054view
2026-06-054view
2026-06-054view
2026-06-054view
2026-06-054view
2026-06-058-Kview
2026-05-114view
2026-05-114view
2026-05-114view

The Long Run

FY 2011–2025 · 15 years

LineLatestCAGRTrend
Revenue$219.86M+10.3%
Gross profit$150.90M+9.6%
Operating income$36.71M+23.3%
Net income$44.04M+26.7%
Cash from ops$36.75M+27.8%

Indices

S&P SmallCap 600

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$80.69$81.88$79.97$81.52230.30K
Sep 24$80.64$81.37$79.67$80.82321.30K
Sep 23$80.70$81.52$79.84$80.58247.10K
Sep 22$79.84$81.32$79.69$80.98260.90K
Sep 21$78.87$79.50$78.22$79.20221.50K

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →